Prestige Consumer Healthcare Inc. (NYSE:PBH) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) have earned a consensus recommendation of “Moderate Buy” from the eight analysts that are covering the stock, MarketBeat Ratings reports. Four analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $85.3333.

PBH has been the topic of a number of research analyst reports. Jefferies Financial Group dropped their price target on shares of Prestige Consumer Healthcare from $75.00 to $71.00 and set a “hold” rating on the stock in a research note on Monday, October 27th. Oppenheimer dropped their target price on shares of Prestige Consumer Healthcare from $82.00 to $72.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 21st. Zacks Research raised shares of Prestige Consumer Healthcare from a “strong sell” rating to a “hold” rating in a research note on Monday, November 10th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Prestige Consumer Healthcare in a research note on Wednesday, October 8th. Finally, Canaccord Genuity Group cut their price objective on Prestige Consumer Healthcare from $100.00 to $88.00 and set a “buy” rating for the company in a research note on Friday, November 7th.

Prestige Consumer Healthcare Stock Down 0.5%

PBH opened at $62.34 on Friday. The company has a fifty day moving average of $60.74 and a two-hundred day moving average of $67.64. The stock has a market capitalization of $3.00 billion, a price-to-earnings ratio of 15.47, a PEG ratio of 1.97 and a beta of 0.39. Prestige Consumer Healthcare has a fifty-two week low of $57.25 and a fifty-two week high of $90.04. The company has a debt-to-equity ratio of 0.55, a quick ratio of 2.51 and a current ratio of 3.70.

Prestige Consumer Healthcare (NYSE:PBH) last posted its earnings results on Thursday, November 6th. The company reported $1.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.97 by $0.10. Prestige Consumer Healthcare had a net margin of 18.09% and a return on equity of 12.43%. The business had revenue of $274.11 million for the quarter, compared to analyst estimates of $257.14 million. During the same period in the prior year, the company posted $1.09 EPS. The company’s revenue for the quarter was down 3.4% on a year-over-year basis. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.580 EPS. On average, research analysts expect that Prestige Consumer Healthcare will post 4.5 earnings per share for the current year.

Insider Buying and Selling

In other Prestige Consumer Healthcare news, VP Jeffrey Zerillo sold 719 shares of the firm’s stock in a transaction on Friday, November 28th. The stock was sold at an average price of $60.00, for a total value of $43,140.00. Following the transaction, the vice president owned 42,329 shares in the company, valued at approximately $2,539,740. This trade represents a 1.67% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 1.40% of the company’s stock.

Hedge Funds Weigh In On Prestige Consumer Healthcare

Several hedge funds and other institutional investors have recently modified their holdings of the business. Nuveen LLC purchased a new stake in Prestige Consumer Healthcare during the 1st quarter valued at about $8,323,000. Russell Investments Group Ltd. grew its position in shares of Prestige Consumer Healthcare by 2.0% in the first quarter. Russell Investments Group Ltd. now owns 28,115 shares of the company’s stock valued at $2,417,000 after purchasing an additional 561 shares in the last quarter. Fox Run Management L.L.C. acquired a new stake in shares of Prestige Consumer Healthcare in the first quarter valued at approximately $254,000. Raymond James Financial Inc. lifted its position in Prestige Consumer Healthcare by 4.2% during the first quarter. Raymond James Financial Inc. now owns 568,178 shares of the company’s stock worth $48,846,000 after buying an additional 22,738 shares in the last quarter. Finally, Northern Trust Corp boosted its stake in Prestige Consumer Healthcare by 4.8% during the first quarter. Northern Trust Corp now owns 852,274 shares of the company’s stock worth $73,270,000 after buying an additional 39,198 shares during the last quarter. 99.95% of the stock is owned by hedge funds and other institutional investors.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).